Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

84.39 +1.33 (+1.60%)

Streaming Delayed Price Updated: 11:43 AM EST, Feb 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 29, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals Earnings Preview ↗

October 28, 2025

Via Benzinga

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

October 27, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

October 23, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗

September 23, 2025

Via Stocktwits

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

October 21, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗

October 16, 2025

Via Benzinga

Ionis to hold third quarter 2025 financial results webcast

October 16, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength ↗

October 15, 2025

IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.

Via Chartmill

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike ↗

October 08, 2025

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.

Via Investor's Business Daily

This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

October 08, 2025

Via Benzinga

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

October 07, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

September 23, 2025

From Biogen Inc.

Via GlobeNewswire

What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗

September 23, 2025

Via Benzinga

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial ↗

September 22, 2025

Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data.

Via Benzinga

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

September 22, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

September 19, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

September 18, 2025

From Biogen Inc.

Via GlobeNewswire

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

September 12, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status ↗

September 09, 2025

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

Via Benzinga

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

September 09, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to host investors and analysts for Innovation Day 2025

September 08, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

September 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies ↗

September 02, 2025

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction ↗

September 02, 2025

Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.